Korean J Hematol 2006; 41(1):
Published online March 30, 2006
https://doi.org/10.5045/kjh.2006.41.1.66
© The Korean Society of Hematology
송은기, 이나리, 임창열
전북대학교 의과대학 내과학교실, 임상의학연구소
We report here on a case of colonic extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) in a 17-year-old male with a history of selective IgA deficiency. The colonoscopic findings showed prominent lymphoid hyperplasia along the terminal ileum and multiple ulceroinfiltrative nodular lesions at the transverse colon and rectum. Immunohistochemically, an extensive infiltration by a CD20-positive lymphoid cell population that displayed a prominent lymphoepithelial structure was detected. Multiple hypermetabolic lymph nodes were found in the cervical, axillary, mediastinal and abdominal regions, in addition to the colon, by performing PET-CT. After administering rituximab weekly for 4 weeks, he had significant regression of the colonic lesions and the lesions in multiple lymph nodes. He remains progression free 10 months after finishing the treatment. This case report demonstrates the potential efficacy of rituximab as a single therapeutic agent for patients with colonic extranodal marginal zone B-cell lymphoma, and even for a patient with an extensive disease status.
Keywords Colon, Extranodal marginal zone B-cell lymphoma, Rituximab
Korean J Hematol 2006; 41(1): 66-70
Published online March 30, 2006 https://doi.org/10.5045/kjh.2006.41.1.66
Copyright © The Korean Society of Hematology.
송은기, 이나리, 임창열
전북대학교 의과대학 내과학교실, 임상의학연구소
Eun Kee Song, Na Ri Lee, Chang Yeol Yim
Department of Internal Medicine, Research Institute of Clinical Medicine, Chonbuk National University, Medical School, Jeonju, Korea
We report here on a case of colonic extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) in a 17-year-old male with a history of selective IgA deficiency. The colonoscopic findings showed prominent lymphoid hyperplasia along the terminal ileum and multiple ulceroinfiltrative nodular lesions at the transverse colon and rectum. Immunohistochemically, an extensive infiltration by a CD20-positive lymphoid cell population that displayed a prominent lymphoepithelial structure was detected. Multiple hypermetabolic lymph nodes were found in the cervical, axillary, mediastinal and abdominal regions, in addition to the colon, by performing PET-CT. After administering rituximab weekly for 4 weeks, he had significant regression of the colonic lesions and the lesions in multiple lymph nodes. He remains progression free 10 months after finishing the treatment. This case report demonstrates the potential efficacy of rituximab as a single therapeutic agent for patients with colonic extranodal marginal zone B-cell lymphoma, and even for a patient with an extensive disease status.
Keywords: Colon, Extranodal marginal zone B-cell lymphoma, Rituximab
Sung Hwa Bae, Sung-Hyun Kim, Soo-Mee Bang
Blood Res 2022; 57(S1): S37-S43Woojung Jeon, Young Kwon Koh, Sunghan Kang, Hyery Kim, Kyung-Nam Koh, Ho Joon Im
Blood Res 2022; 57(1): 41-50Yoon Seok Choi
Blood Res 2020; 55(S1): S58-S62